In this interview with Lucinda Orsini, D.P.M., M.P.H., the Associate Chief Science Officer for the Professional Society for Health Economics and Outcomes Research (ISPOR), she shares her views on navigating the opportunities and challenges of working with RWE. Dr. Orsini sees substantial opportunity for RWE in the regulatory space, ” We will increasingly see regulators, HTA bodies, and payers looking to real-world data to support decisions, and to revisit decisions over time as more data becomes available. Are there different patients that are benefitting now than at the time of approval? Has a new safety profile come up? I see that as the next “wave” for the use of RWE.”
Orsini weighs in on ISPOR’s Transparency Initiative and how this advances RWE, as well as hurdles to wider-spread use of RWE and opportunities/challenges for payers and HTAs when using RWE for value assessments.
To read more, click here.
(Source: Aetion, July 17, 2020)